Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

3.730 +0.090 (+2.47%)
Streaming Delayed Price Updated: 10:14 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revance Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
From Revance Therapeutics, Inc.
Via Business Wire
Revance Provides Corporate Update at Investor Day
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Host Investor Day on September 19, 2023
From Revance Therapeutics, Inc.
Via Business Wire
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the Needham 22nd Annual Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. 
Via MarketBeat
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.